Assertio Holdings, Inc. (ASRT)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Total revenues | 29,222 | 26,488 | 29,204 | 31,126 |
| Change in fair value of contingent consideration | - | - | 300 | - |
| Selling, general and administrative expenses | 16,960 | 21,975 | 16,726 | 18,385 |
| Restructuring charges | - | 289 | - | - |
| Research and development expenses | 387 | 438 | 1,005 | 798 |
| Cost of sales | 10,677 | 7,786 | 7,550 | 8,889 |
| Amortization of intangible assets | 9,233 | 9,233 | 6,671 | 6,671 |
| Total costs and expenses | 37,257 | 39,721 | 32,252 | 34,743 |
| Loss from operations | -8,035 | -13,233 | -3,048 | -3,617 |
| Other gain (loss) | - | - | 45 | 8 |
| Interest expense | - | 765 | 761 | 758 |
| Other gain (loss) | 6 | -18 | - | - |
| Interest income | 675 | 720 | 887 | 842 |
| Interest expense | 768 | - | - | - |
| Loss on assertio therapeutics divestiture | -8,174 | - | - | - |
| Total other (expense) income | -8,261 | -63 | 171 | 92 |
| Net loss before income taxes | -16,296 | -13,296 | -2,877 | -3,525 |
| Income tax expense | 56 | 245 | 44 | 149 |
| Income tax expense | 100 | - | - | - |
| Net loss and comprehensive loss | -16,352 | -13,541 | -2,921 | -3,674 |
| Basic net loss per share (in dollars per share) | -0.17 | -0.14 | -0.03 | -0.04 |
| Diluted net loss per share (in dollars per share) | -0.17 | -0.14 | -0.03 | -0.04 |
| Shares used in computing basic net loss per share (in shares) | 95,970,000 | 95,677,000 | 95,352,000 | 95,240,000 |
| Shares used in computing diluted net loss per share (in shares) | 95,970,000 | 95,677,000 | 95,352,000 | 95,240,000 |